Crypto Has Lost More Than Half Its Value in Eight Months

The crypto market is in the middle of one of the most sustained drawdowns in its history, and there is no clear sign it has found a bottom. The total market capitalization of cryptocurrency has erased more than half its value in just eight months. After peaking at a record $4.3 trillion on October 6, 2025, the total crypto market is now worth approximately $2.0 trillion — a 54% decline over 261 days. That works out to an average of roughly $8.8 billion in value erased every single day for nearly nine consecutive months.

Bitcoin, the sector’s bellwether, is trading just below $59,200, down nearly 1% on the session and well off the highs above $100,000 it commanded earlier in this cycle.

Why the Selloff Makes Sense

The pullback, while severe, is not difficult to explain. Crypto is among the highest-risk, most speculative asset classes in the market, and the macro environment of 2026 has been actively hostile to risk. Inflation running at 4.2%, a Federal Reserve under new chair Kevin Warsh that has dropped its easing bias and signaled potential rate hikes before year-end, persistent geopolitical tension from the Iran conflict, and a broad repricing of stretched valuations across speculative assets have all weighed heavily on the space. Crypto has become increasingly sensitive to interest rate expectations, and a higher-for-longer rate environment removes much of the cheap, abundant risk capital that fueled prior bull runs.

There is also a competition-for-capital dynamic worth noting. The wave of high-profile AI IPOs in 2026 — Cerebras, SpaceX, and the anticipated Anthropic and OpenAI listings — has absorbed an enormous amount of the speculative risk capital that historically flowed into crypto during bull cycles. When investors can buy generational growth stories in the public markets, the appetite for digital assets diminishes.

The Case for Patience

Not everyone views the current drawdown as a reason to abandon the space. A long-cycle perspective on crypto notes that winters have repeatedly come and gone while the underlying industry continued to grow — the prior cycle bottomed near $16,000 four years ago, which makes the current $60,000 level appear relatively elevated by historical standards. The bull case from here rests on a familiar set of catalysts: clearer regulatory market structure, favorable legislation, continued development of real-world use cases, and the eventual return of risk capital once the current wave of AI companies completes their public offerings and post-IPO share lockups expire. Whether those catalysts materialize on any near-term timeline remains the central open question.

The Equity Market Alternative

For investors, the crypto drawdown raises a practical question worth considering: why attempt to time a bottom in one of the market’s most volatile asset classes when public equities are offering clear, fundamentals-driven opportunities? The contrast is stark. While crypto sheds billions daily, companies tied to the AI infrastructure buildout — including memory and semiconductor names posting blowout earnings and raising guidance — are demonstrating measurable revenue growth and expanding margins.

This is not a dismissal of crypto’s long-term potential, which remains a genuine debate. But for investors focused on opportunities grounded in earnings, cash flow, and visible demand, the public markets — including the small and microcap names feeding the AI supply chain — currently offer compelling alternatives that do not require catching a falling knife. Sometimes the better opportunity is the one hiding in plain sight.

Tectonic Metals Inc. (TETOF) – Alaska’s Next Tier One Gold Deposit?


Thursday, June 25, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. We are initiating coverage of Tectonic Metals Inc. with an Outperform rating and price target of US$3.50 (C$4.85) per share. In our view, Tectonic’s Flat Gold Project, located in the prolific Kuskokwim Mineral Belt in Alaska, offers the potential to become a Tier 1 gold mine which are generally defined as those producing at least 500 thousand gold ounces per year, exhibit a mine life of 10+ years, with costs in the lower half of the global industry cost curve. Based on drilling results to date, we estimate a potential mineral endowment of at least 5.3 million gold ounces with significant growth prospects. Tectonic expects to publish an initial resource estimate in the first quarter of 2027.

Exploration and drilling program yields significant discoveries. Drilling at the Flat Gold Project continues to demonstrate scale, with mineralization at the Chicken Mountain target now defined over approximately 3.3 kilometers of strike length, widths of up to 700 meters, and depths exceeding 300 meters while remaining open in all directions. All 191 holes drilled at Chicken Mountain have intersected gold mineralization, with 117 of 191 holes ending in mineralization.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Xcel Brands (XELB) – The Transformation Takes Shape


Thursday, June 25, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Commercialization phase begins. Following several years of portfolio repositioning and infrastructure investment, Xcel has begun commercializing its next generation of creator-led brands, marking a transition from strategy development to revenue execution.

Creator-commerce platform differentiates the investment story. Unlike traditional consumer products companies, Xcel leverages established creators with highly engaged audiences to develop brands across Fashion, Food & Beverage, Pet, and Home, creating an asset-light, royalty-driven business model with meaningful operating leverage.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NeuroSense Therapeutics Ltd. (NRSN) – Phase 2 RoAD Trial Findings In Alzheimer’s Disease Reported


Thursday, June 25, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Supports Mechanism of Action. NeuroSense reported data from its Phase 2 RoAD trial testing PrimeC in Alzheimer’s Disease (AD). The study was designed to evaluate safety, efficacy, and disease-associated biomarkers. The results showed changes consistent with the prevention of degeneration and neuronal cell death. We believe these data support PrimeC’s mechanism and its benefits, providing proof of concept for further studies.

Study Design. The Phase 2 RoAD trial was a placebo-controlled study testing PrimeC in Alzheimer’s disease. The trial enrolled eight patients who were randomized to receive PrimeC or placebo for 52 weeks. Three participants completed a 12-month follow-up period, with CSF and plasma samples evaluated at three timepoints.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – AI Launch Supports Transformation


Thursday, June 25, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

The launch of the AI-powered Next Generation CX Platform reinforces strategic transformation. Conduent introduced new AI-enabled capabilities, including real-time translation, AI-driven agent training, and voice enhancement technologies, further positioning the company as a technology-enabled customer experience provider rather than a traditional business process outsourcer.

New capabilities support higher-margin, technology-enabled growth. The platform enables real-time translation across more than 90 languages, AI-based training simulations that can reduce agent onboarding time by up to 40%, and accent smoothing and noise cancellation, all of which enhance customer interactions and improve operational efficiency.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Small Cap Biotech Is Where the Catalysts Are Right Now

While the broader market spent June fixated on the SpaceX IPO, the Federal Reserve transition, and a chip-driven selloff, something quieter and arguably more consequential has been building in small cap biotech. Over the past several weeks, the sector has produced a steady stream of value-moving catalysts — reverse mergers, patent wins, acquisitions at steep premiums, and AI partnerships — that collectively point to one of the most active catalyst environments the space has seen in years. For investors who understand how small cap biotech actually creates value, that activity is worth paying close attention to.

A Cluster of Catalysts in a Single Month

The pace has been striking. On Tuesday alone, three separate small cap biotech stories moved sharply. Boundless Bio surged roughly 75% after announcing a reverse merger with privately held Serapha Bio, pivoting the public company toward a gene editing therapy for a serious inherited disease while distributing excess cash to existing shareholders. CervoMed soared 61% on a key patent win for its dementia drug candidate. Butterfly Network jumped 33% on an expanded medical imaging partnership with AI company Midjourney.

Those single-day moves did not happen in isolation. Earlier in June, GSK agreed to acquire Nuvalent for $10.6 billion — a 40% premium — to gain access to its precision lung cancer pipeline. AbbVie followed with a $10.9 billion all-cash acquisition of immunology drug maker Apogee Therapeutics. Each of these transactions reflects the same underlying dynamic playing out at different scales.

Why Catalysts Concentrate in Small Cap Biotech

Unlike most sectors, where stock prices tend to move incrementally with earnings and macro conditions, small cap biotech is fundamentally a catalyst-driven asset class. A clinical-stage company often has no revenue and no approved products. Its entire value rests on the probability-weighted potential of its pipeline — and that value can reprice dramatically and instantly when a binary event occurs.

Those events take predictable forms. FDA decisions and breakthrough designations validate a drug’s regulatory path. Clinical trial data readouts confirm or refute a therapy’s efficacy. Patent rulings protect or expose a company’s competitive position. Acquisitions by large pharmaceutical companies crystallize value at a premium. And reverse mergers transform a stalled public shell into a vehicle for a more promising private asset. Each of these can move a small cap biotech 30%, 50%, or more in a single session — moves that simply do not happen with the same frequency or magnitude anywhere else in the public markets.

The Structural Forces Behind the Surge

The current wave is being driven by forces that are unlikely to reverse soon. Large pharmaceutical companies are facing significant patent cliffs over the next several years and are aggressively acquiring external innovation to replace expiring revenue. The pipeline of clinical-stage companies with validated assets in the sub-$2 billion market cap range remains deep. And next-generation technologies — gene editing, precision oncology, AI-enabled diagnostics — are moving from theoretical promise toward clinical proof of concept, creating fresh acquisition and partnership targets.

For investors, the takeaway is not that every small cap biotech is a winner. The opposite is true: the same binary nature that produces enormous gains also produces sharp losses when trials fail or approvals are denied. The risk is real and concentrated. But the catalyst density in this corner of the market is exactly what makes it one of the most closely watched spaces in small cap investing right now. The companies producing these moves were, in many cases, trading well below the radar of mainstream coverage just weeks ago.

That is precisely where the most significant repricing tends to happen first.

Russell Reconstitution Day Approaches: Small Caps Prepare for a Surge in Trading Activity

The annual Russell Index reconstitution becomes official after the market closes on Friday, June 26, setting the stage for one of the busiest trading sessions of the year for small-cap stocks.

While the event occurs every June, this year’s reconstitution arrives amid renewed investor interest in small caps and follows a strong first half for many emerging growth companies. As index funds and ETFs rebalance portfolios to reflect the new membership lists, millions of shares are expected to change hands during Friday’s closing auction.

For companies being added to the Russell 2000 and Russell Microcap indexes, inclusion can provide increased visibility, improved liquidity, and exposure to a broader institutional investor base.

Hundreds of Companies Set to Join Russell Indexes

FTSE Russell’s preliminary lists show hundreds of companies scheduled for addition across the Russell index family. The Russell 2000 is expected to add more than 200 companies, while numerous smaller firms will enter the Russell Microcap Index.

Several notable additions have already attracted investor attention, particularly among healthcare, technology, industrial, and defense-related companies. Healthcare remains the largest source of new additions, reflecting the continued recovery in small-cap biotech valuations. Technology and industrial companies also represent a significant portion of new constituents.

Why Friday Matters

The actual reconstitution occurs during the closing auction on Friday, often producing extraordinary trading volumes in affected stocks.

Passive funds tracking Russell indexes must adjust their holdings to match the updated index composition. This creates concentrated buying in newly added companies and selling in stocks being removed.

For some smaller companies, the volume traded during the closing auction can exceed multiple days’ worth of normal trading activity.

Historically, stocks scheduled for inclusion often experience elevated volume leading into reconstitution day as traders attempt to position ahead of index fund purchases. The largest impact, however, typically occurs during the final minutes of trading on the effective date.

Institutional Visibility Can Be a Catalyst

Although index inclusion does not change a company’s fundamentals, it can increase awareness among institutional investors that may have previously overlooked the stock.

For smaller companies, particularly those transitioning from micro-cap status, Russell inclusion often serves as a milestone. Increased liquidity can improve trading efficiency, broaden ownership, and potentially attract additional analyst coverage.

Investors should remember that index inclusion alone rarely drives long-term performance. Ultimately, earnings growth, execution, and capital allocation remain the primary determinants of shareholder returns.

Looking Beyond Reconstitution Day

Once Friday’s rebalance is complete, attention will shift from index mechanics back to fundamentals.

Nevertheless, Russell reconstitution remains one of the most important annual events for the small-cap market. For investors, it provides a snapshot of which companies have achieved sufficient scale and market value to earn inclusion in one of the most widely followed small-cap benchmarks.

As the closing bell approaches on Friday, traders and portfolio managers alike will be watching closely as billions of dollars are repositioned across the small-cap landscape.

Notable Companies Joining the Russell Indexes

This year’s reconstitution includes companies from a wide range of industries, underscoring the diversity of today’s small-cap market. Among the companies expected to be added to the Russell indexes are Conduent (NASDAQ: CNDT), Star Equity Holdings (NASDAQ: STRR), The Beachbody Company (NYSE: BODI), Vince Holding Corp. (NYSE: VNCE), Commercial Vehicle Group (NASDAQ: CVGI), FreightCar America (NASDAQ: RAIL), Ocugen (NASDAQ: OCGN), Twin Disc (NASDAQ: TWIN), and Unicycive Therapeutics (NASDAQ: UNCY).

The additions span sectors including business services, industrials, consumer discretionary, transportation, healthcare, and technology. Russell membership is determined through FTSE Russell’s annual reconstitution process, which ranks eligible U.S. companies by market capitalization and other index criteria. The final index changes become effective after the market closes on June 27.

Power Metallic Mines Inc. (PNPNF) – Power Metallic Advances Toward Key Resource Milestone with New High-Grade Results


Wednesday, June 24, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Recent drilling results. Power Metallic Mines reported additional assay results from its Winter 2026 drilling program at the Lion Zone, with the results expected to support the company’s initial NI 43-101 Mineral Resource Estimate (MRE), which is scheduled for completion by the end of July. The MRE for both the Lion Zone and the Nisk deposit will provide the foundation for a Preliminary Economic Assessment (PEA) that is expected to begin immediately afterward.

Strong near-surface copper grades. The latest drilling focused on infill holes designed to improve confidence in resource modeling along the western side of the Lion Zone, particularly within a potential future open-pit area. Results continue to demonstrate strong near-surface mineralization, highlighted by Hole PML-26-115, which returned 13.3 meters grading 3.98% copper equivalent (CuEq) beginning just 25 meters below surface, including a higher-grade interval of 3.77 meters grading 9.36% CuEq. Hole PML-26-105 also delivered a strong intercept of 5.26 meters grading 8.45% CuEq at a depth of approximately 140 meters. Both will be included in the upcoming MRE.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Boundless Bio Pivots From Cancer to a Rare Genetic Disease in a Reverse Merger With Serapha Bio

In a transaction that illustrates how struggling clinical-stage biotechs are increasingly being repurposed as vehicles for more promising assets, Boundless Bio (Nasdaq: BOLD) announced Tuesday it has entered into a definitive all-stock merger agreement with privately held Serapha Bio. The deal will see Serapha combine with Boundless Bio and effectively take over the public company, pivoting the combined entity away from Boundless’s cancer research and toward Serapha’s gene editing therapy for a serious inherited disease. Boundless Bio shares surged approximately 75% on the news to around $2.50.

Upon completion, the combined company will operate under the name Serapha Bio and is expected to trade on Nasdaq under the new ticker symbol “AATD” — a direct reference to the disease its lead program targets.

The Structure of the Deal

This is a reverse merger, a structure in which a private company merges into a public one to gain a stock market listing without conducting a traditional IPO. The ownership split makes the dynamic clear: pre-merger Boundless Bio stockholders are expected to own approximately 3.7% of the combined company, while pre-merger Serapha stockholders — including investors participating in the concurrent financing — will own approximately 96.3%.

Two features make this transaction particularly notable for shareholders. First, alongside the merger, Serapha is raising $230 million in a concurrent private placement co-led by RTW Investments and RA Capital Management, with participation from a syndicate of top healthcare investors and mutual funds. That level of institutional backing provides the combined company with substantial capital to advance its lead program through clinical development. Second, prior to closing, Boundless Bio expects to declare a cash dividend to its pre-merger stockholders to distribute excess net cash, currently estimated at approximately $44 million to $48 million. That dividend, combined with the stock’s jump, gives existing Boundless holders both an immediate cash return and continued exposure to the new program.

What Serapha Is Actually Developing

Serapha’s lead program, SERP-01, is an investigational in vivo base editing therapy targeting Alpha-1 Antitrypsin Deficiency, a serious inherited genetic disorder that can cause progressive lung and liver disease. The therapy specifically targets the SERPINA1 E342K mutation — known as the PiZZ genotype — which is the most common cause of severe AATD. The company has reported proof-of-concept data demonstrating restoration of serum AAT to normal levels, an encouraging early signal for a disease that currently has limited treatment options.

The asset has an international development backstory. Serapha licensed SERP-01, developed as YOLT-202 in Greater China, from YolTech Therapeutics in June 2026 in exchange for an upfront cash payment and a minority equity stake. Under the agreement, YolTech is eligible to receive regulatory and commercial milestones totaling over $2 billion plus tiered royalties, while retaining development and commercialization rights for the Greater China territory. YolTech has been enrolling AATD patients in an investigator-initiated trial at Renji Hospital in Shanghai.

The Small Cap Biotech Read

For investors tracking the small and microcap biotech space, this transaction reflects a pattern that has become increasingly common in 2026. Clinical-stage companies whose original programs have stalled or been deprioritized are valuable to private biotechs precisely because of what they already possess: a Nasdaq listing, a cash balance, and an existing shareholder base. Rather than navigate the lengthy and uncertain IPO process, a promising private company like Serapha can access public markets, raise institutional capital, and advance its lead asset all in a single coordinated transaction.

The base editing space in particular has attracted significant investor attention as next-generation gene editing technologies move from theoretical promise toward clinical proof of concept. With $230 million in fresh capital, validated early data, and a clear regulatory target in a serious genetic disease, the newly formed Serapha Bio enters the public market positioned to advance one of the more closely watched programs in the in vivo base editing field. The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.

Energy Fuels Makes a $1.9 Billion Bet to Build a Western Rare Earth Supply Chain From Mine to Magnet

In one of the most strategically significant critical minerals deals of the year, Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced Tuesday it has entered into a definitive agreement to acquire Vacuumschmelze GmbH & Co. KG and its affiliated entities — collectively known as VAC — from private equity firm Ara Partners in a cash-and-stock transaction valued at approximately $1.9 billion. The deal is designed to create a fully integrated rare earth supply chain spanning everything from mining through finished permanent magnet manufacturing, reducing Western dependence on China for materials that are essential to defense, automotive, robotics, and data center applications.

The transaction values VAC at $1.9 billion based on Energy Fuels’ closing share price of $16.12 on June 22, and is structured as $718 million in cash plus 65.853 million newly issued Energy Fuels shares. Energy Fuels will also assume approximately $140 million of VAC’s adjusted net debt. Energy Fuels shares slipped roughly 2% in premarket trading following the announcement, a common reaction when an acquirer issues significant new equity to fund a large deal.

What Energy Fuels Is Acquiring

VAC is not an early-stage company. Headquartered in Hanau, Germany, the business brings more than 100 years of advanced magnetics expertise, over 400 patents, more than 1,000 customers, and manufacturing operations across North America, Europe, and Asia. Its most strategically important asset is a recently commissioned permanent magnet facility in Sumter, South Carolina, which currently has capacity for 2,000 tonnes per year of rare earth permanent magnets and is scalable to 12,000 tonnes per year.

Permanent magnets are the critical end product in the rare earth value chain. They are essential components in electric vehicle motors, wind turbines, defense systems, robotics, and the cooling and power infrastructure inside AI data centers. The overwhelming majority of global permanent magnet production currently takes place in China, which has made supply chain security in this category a top priority for the United States and its allies.

The Mine-to-Magnet Strategy

The strategic logic behind the deal is vertical integration across the entire rare earth value chain. Energy Fuels brings the upstream capabilities — mining, processing, and refining — anchored by its White Mesa Mill in Utah, the only conventional uranium and rare earth processing facility of its kind in the United States. VAC contributes the downstream capabilities of metals and alloy production and finished magnet manufacturing.

Combining the two creates what the company describes as a fully integrated mine-to-magnet platform. Under the plan, rare earth oxides produced at the White Mesa Mill would be converted into metals and alloys at facilities in Korea and the United States, then manufactured into finished permanent magnets at VAC’s Sumter facility and its European operations. The Sumter site is also expected to be fed by rare earth oxides from Energy Fuels’ Donald Project in Australia, which is anticipated to reach a final investment decision in the third quarter of 2026 and be commissioned in 2028.

The Government Backing

The deal does not stand alone. Just last week, Energy Fuels announced it had received conditional US government support to accelerate its growth in rare earths and critical materials, including a $725 million conditional loan from the US Office of Strategic Capital. That federal backing reflects the strategic priority Washington has placed on building domestic and allied critical minerals supply chains, a theme that has run through multiple government interventions in 2026 including stakes in quantum computing companies and rare earth miners.

For investors tracking the critical minerals and rare earth space, the Energy Fuels-VAC combination represents one of the clearest examples yet of a smaller company moving aggressively to build a fully integrated, government-supported alternative to Chinese supply chain dominance. As demand for permanent magnets accelerates across defense, electric vehicles, robotics, and AI infrastructure, control of the full value chain from mine to finished magnet is becoming one of the most strategically valuable positions in the entire materials sector.

Eledon Pharmaceuticals (ELDN) – Eledon Presents Data Update From Phase 2 Trial With Clinical Trial Plans


Tuesday, June 23, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Long-Term Outcomes Favor Tegoprubart. Eledon presented long-term data from its Phase 2 BESTOW trial at the American Transplantation Congress (ATC). The BESTOW trial tested tegoprubart as part of the immunosuppressive regimen for patients receiving kidney transplants. Data from the Open Label Extension study showed consistent improvements in kidney function and a reduction in rejection episodes. Importantly, the side effect profile continues to show significant  improvements over tacrolimus, the standard of care.

Trial Background. The Phase 2 BESTOW trial was a double-blind study testing tegoprubart as an immunosuppressive after kidney transplantation. An active comparator arm included tacrolimus as an immunosuppressive. The primary endpoint of the trial was eGFR (estimated Glomerular Filtration Rate) and BPAR (Biopsy Proven Acute Rejection) episodes. Following the completion of the 12-month course of treatment, patients were given the option to continue in an Open Label Extension (OLE) study.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Markets Reopen Into a Week That Could Decide Whether the Fed Hikes in 2026

US markets returned Monday from the Juneteenth holiday weekend and walked straight into one of the most consequential data weeks of the year. After Federal Reserve Chair Kevin Warsh’s hawkish debut last Wednesday — which saw the central bank hold rates while signaling that nine of 18 officials now project at least one rate hike before year-end — the coming days will deliver the economic readings that determine whether that hike moves from projection to reality. For small and microcap investors, this is the week the second half of 2026 takes shape.

The May PCE Reading Is the Number That Matters

The single most important data point this week arrives Friday with the release of the May Personal Consumption Expenditures price index — the Fed’s preferred inflation gauge. While the Consumer Price Index gets more headlines, PCE is the measure the FOMC actually uses to assess progress toward its 2% target, which makes Friday’s print the most direct evidence yet of whether inflation is cooling or entrenching.

The context heightens the stakes. May CPI came in at 4.2% year over year, the highest in three years, driven heavily by energy costs tied to the now-easing US-Iran conflict. If PCE confirms that inflation pressure, it strengthens the case for the rate hike the dot plot is signaling. If it shows the energy spike was the dominant and possibly peaking driver — with core inflation more contained — it gives the Fed room to hold without tightening further. Either outcome moves Treasury yields, and Treasury yields move small caps.

GDP Revisions Add Another Layer

Before Friday’s inflation data, markets will digest revised first-quarter GDP figures. The revision matters because it recalibrates the growth side of the Fed’s dual mandate. A stronger-than-expected economy gives the committee more justification to tighten without fear of triggering a downturn. A softer reading complicates the hawkish case and raises the specter of stagflation — weak growth paired with stubborn inflation — which is the single most difficult environment for the Fed to navigate and historically the hardest for smaller, rate-sensitive companies to weather.

Earnings Worth Watching

On the corporate side, two bellwether reports land this week. Micron reports quarterly results that will serve as a direct read on AI-driven memory demand, building on the supercycle narrative that has lifted the entire semiconductor space this year. After Broadcom’s recent guidance-driven selloff reset expectations across chip names, Micron’s numbers will test whether the underlying demand story remains intact for the smaller semiconductor and component companies operating downstream of the same AI buildout.

FedEx also reports, and its results function as a broad economic barometer. As a global logistics operator, FedEx’s volume data and forward guidance offer a real-time read on shipping activity, consumer demand, and industrial output — all directly relevant to the domestically focused small caps that make up the Russell 2000.

Why This Week Matters for Small Caps

Small and microcap companies carry disproportionately more variable-rate debt than their large cap counterparts, which means the rate path being shaped this week translates directly into their cost of capital and earnings trajectory. The Russell 2000 has spent 2026 caught between strong underlying fundamentals — historic valuation discounts, improving earnings growth, and domestic revenue exposure — and a punishing rate environment that has capped its performance relative to large caps.

This week’s data will tilt that balance. A benign PCE print and solid GDP would support the case that the Fed can hold rather than hike, removing an overhang that has weighed on smaller companies all year. A hot inflation reading paired with strong growth would validate the hawkish dot plot and extend the higher-for-longer environment further into the future. Either way, by Friday afte

Alan Greenspan, the Most Powerful Central Banker of His Era, Dies at 100

Alan Greenspan, who chaired the Federal Reserve for more than 18 years across four presidential administrations and became the most recognizable central banker in modern history, died Monday at his home in Washington from complications of Parkinson’s disease. He was 100 years old. His death, confirmed by his wife of 29 years, NBC News correspondent Andrea Mitchell, closes the book on a figure whose words and decisions shaped American markets for nearly two decades and whose legacy continues to influence how investors and policymakers think about the role of the Fed today.

Few figures in financial history wielded the kind of market-moving power Greenspan commanded. From his appointment by President Reagan in 1987 through his retirement in 2006, his public remarks were parsed word by word by investors, economists, and lawmakers alike. The deliberate ambiguity of his communication style became so well known it earned its own name — “Fedspeak” — a dialect he later admitted he cultivated intentionally to avoid moving markets before the Fed was ready to act.

The Maestro Years

Greenspan presided over one of the longest economic expansions in US history, a boom stretching from 1991 to 2001, and his tenure coincided with the period economists came to call the “Great Moderation” — a stretch of low inflation, steady growth, and rising markets from the mid-1980s through 2007. He broke with central banking orthodoxy by allowing unemployment to fall to historically low levels without preemptively raising rates, a willingness to “watch and wait” that defined his data-driven approach and helped sustain the expansion of the 1990s.

His most enduring contribution to the financial lexicon came in 1996, when he warned of “irrational exuberance” in asset prices — a phrase that sent immediate shivers through global markets even though the dot-com bubble he alluded to would not burst for another five years. The remark captured the paradox of Greenspan’s influence: a single carefully chosen phrase could move markets around the world, yet his broader policy of accommodation often fueled the very exuberance he cautioned against.

A Complicated Legacy

Greenspan’s reputation, near-mythical at the height of his tenure, was significantly complicated by the events that followed his departure. Critics have pointed to his advocacy for financial sector deregulation and his sustained low-rate policies as contributing factors to the asset bubbles that culminated in the 2007-2009 global financial crisis. In 2008 testimony before lawmakers, Greenspan acknowledged he had mistakenly believed major banks would regulate themselves to protect their own shareholders — a candid admission of a flawed assumption at the heart of the crisis.

As one former senior Fed official observed, the near-deification Greenspan received before the crisis was never fully deserved, and the criticism he absorbed afterward was never fully deserved either. The truth of his legacy sits somewhere in between.

Why It Still Matters for Markets Today

Greenspan’s death arrives at a moment of renewed focus on Federal Reserve independence and communication. New Fed Chair Kevin Warsh, who presided over his first FOMC meeting just last week, has openly advocated for a less communicative, less predictable Fed — a notable departure from the era Greenspan defined, in which markets hung on the chairman’s every utterance. Warsh’s decision to slash the Fed’s post-meeting statement to 130 words and withhold his own dot-plot projection reflects a philosophy that stands in deliberate contrast to the Greenspan model.

For investors, Greenspan’s passing is a reminder of how profoundly central bank leadership shapes market conditions across cycles. The debates that defined his tenure — how much the Fed should intervene, how transparent it should be, how much faith to place in market self-correction — remain unresolved and are once again at the center of monetary policy under new leadership. The Maestro has died, but the questions he raised about the Fed’s proper role have never been more relevant.